Prophylaxis in transurethral surgery: oral lomefloxacin versus intravenous cefuroxime.
A randomized study compared the efficacy of a single dose of lomefloxacin given orally vs. cefuroxime given intravenously for prophylaxis against urinary tract infection in patients who were undergoing transurethral surgery. Patient groups were demographically similar; 25 received 400 mg lomefloxacin orally 2-6 h before surgery and 26 received 1.5 g cefuroxime intravenously 30-90 min before surgery. Urine cultures were obtained prior to surgery, 24 h after surgery and 3-5 days after surgery or before hospital discharge. Treatment was considered successful if bacterial culture showed < 10(5) CFU/ml. Clinical results expressed as success/failure rates showed success in 18 patients in the lomefloxacin group (72%) and 15 patients in the cefuroxime group (57.7%). Results demonstrated that lomefloxacin is superior to cefuroxime when used as prophylaxis against urinary tract infection following transurethral surgery. In addition, lomefloxacin may be preferable because of its convenient single-dose oral administration.
Martín-Luengo
F
F
Microbiology Department, General Hospital, Murcia, Spain.
Fontana
L
L
Rico
J L
JL
Tomás-Ros
M
M
Murcia
A
A
Romero
A
A
D000284:Administration, Oral; D000368:Aged; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000517:prevention & control*; D002444:Cefuroxime / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D024841:Fluoroquinolones; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D011292:Premedication; D011446:Prospective Studies; D011467:Prostate / Q000601:surgery; D015363:Quinolones / Q000008:administration & dosage / Q000627:therapeutic use*; D014521:Urethra; D001743:Urinary Bladder / Q000601:surgery; D014566:Urogenital System / Q000601:surgery*
D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D015363:Quinolones; C053091:lomefloxacin; D002444:Cefuroxime